- Home
- BLFS vs COLL Comparison
BLFS vs COLL Comparison
Compare BLFS & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BLFS | COLL |
|---|---|---|
| Founded | 1987 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 923.5M | 1.1B |
| IPO Year | 2013 | 2015 |
Fundamental Metrics
Financial Performance| Metric | BLFS | COLL |
|---|---|---|
| Price | $24.28 | $33.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $32.00 | ★ $51.40 |
| AVG Volume (30 Days) | ★ 485.2K | 385.2K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.27 | N/A |
| EPS | 0.02 | ★ 0.40 |
| Revenue | $96,214,000.00 | ★ $780,567,000.00 |
| Revenue This Year | $19.73 | $8.01 |
| Revenue Next Year | $17.82 | N/A |
| P/E Ratio | $1,208.50 | ★ $84.49 |
| Revenue Growth | 16.97 | ★ 23.62 |
| 52 Week Low | $17.86 | $28.74 |
| 52 Week High | $29.57 | $50.79 |
Technical Indicators
Market Signals| Indicator | BLFS | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 63.86 | 44.10 |
| Support Level | $23.74 | $31.56 |
| Resistance Level | $26.55 | $36.22 |
| Average True Range (ATR) | 1.18 | 1.64 |
| MACD | 0.25 | -0.15 |
| Stochastic Oscillator | 83.54 | 5.92 |
Price Performance
Historical ComparisonAbout BLFS BioLife Solutions Inc.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.